Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, has shown efficacy in ulcerative colitis and was approved by the US Food and Drug Administration (FDA ...

KILLEEN, Texas (KWTX) - “Serenity was a bright, loving, and compassionate young soul with a promising future ahead of her. She brought joy to everyone around her, and her kindness touched so ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...

Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phase 3 trial. The VIVID-1 ...

No association seen for cumulative nonsteroidal anti-inflammatory drug dose with reduced dementia risk. HealthDay News — Long-term nonsteroidal anti-inflammatory drug (NSAID) use is associated ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab).

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Mirikizumab for treating moderately to severely active Crohn's disease [ID6244] Technology appraisal guidance TBC Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ...

[ID6195] Technology appraisal guidance TBC Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473 Technology appraisal ...

In other Lilly news, the FDA recently approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. The drug is is now approved in the United States ...